Table 5 Effect of SOR-MIL-53 nanocomposite on the different phases of the cell cycle as analyzed by flow cytometry in HepG2 cell line after 24 h treatment.

From: MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro

Nanocomposite

Treatment

%G0-G1

%S

%G2-M

SOR-MIL-53

Untreated HepG2 Control

64.00 ± 4.03

36.32 ± 1.23

0.55 ± 0.17

IC50 (23.49 µg/ml)

93.12 ± 2.16*↑

6.32 ± 2.34*↓

0.68 ± 0.95

P-value

0.0004

0.00004

0.83

Back to article page